Form 4 for RYTM RHYTHM PHARMACEUTICALS, INC.
Accepted 2026-09-01 16:22:52 ET · period of report 2026-08-31 · accession 0001649904-26-000023 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-01 16:22 | 2026-08-31 | RYTM | Smith Hunter C | CFO | M - OptEx | $25.79 | +57.2K | 176.8K | +48% | +$1.47M |
| DMT | 2026-09-01 16:22 | 2026-08-31 | RYTM | Smith Hunter C | CFO | S - Sale+OE | $105.46 | -62.8K | 114.0K | -36% | -$6.62M |
| DT | 2026-09-01 16:22 | 2026-08-31 | RYTM | Smith Hunter C | CFO | M - OptEx | $0.00 | -57.2K | 3,813 | -94% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-31 | M | A | 57,187 | $25.79 | 176,798 | D | — | — | (F1) The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. |
| 2 | Common | Common Stock | 2026-08-31 | S | D | 23,072 | $104.59 | 153,726 | D | — | — | (F1) The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. (F2) The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $104.04 to $105.03 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-08-31 | S | D | 11,514 | $105.37 | 142,212 | D | — | — | (F1) The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. (F3) The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.04 to $106.01 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2026-08-31 | S | D | 28,188 | $106.20 | 114,024 | D | — | — | (F1) The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. (F4) The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $106.05 to $106.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 5 | Derivative | Employee Stock Option (Right to Buy) | 2026-08-31 | M | D | 57,187 | $0.00 | 3,813 | D | $25.79 · — to 2028-02-13 | 57,187 Common Stock | (F1) The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. (F5) This option was granted on February 14, 2018 and the shares underlying this option vested in sixteen equal quarterly installments. |